Introduction Cancer care in India faces a brutal affordability problem. India has 1.46 million new cancer cases per year and over 800,000 deaths annually. The majority of patients pay out-of-pocket because most cancer immunotherapy and targeted therapy drugs are not covered under Ayushman Bharat. In Budget 2026-27, the government responded with a targeted fiscal intervention: exempting 17 cancer drugs and a range of rare disease medicines from customs duty to directly lower import costs and retail prices. For oncologists, this is clinically relevant because it changes the affordability conversation with patients immediately. What the Budget Actually Did Budget 2026-27 exempted 17 specific cancer drugs from customs duty. Named drugs include Ribociclib (CDK4/6 inhibitor used in HR-positive metastatic breast cancer) and Brigatinib (ALK inhibitor for ALK-positive non-small cell lung cancer). Rare disease medicines also received customs duty exemptions. Simultaneously, Budget 2026 established new Trauma Centers in every district hospital and increased PM-ABHIM allocations for cancer screening and treatment infrastructure. The government also boosted the biologics and biosimilars production fund with a Rs 10,000 crore outlay to accelerate domestic manufacture of these drugs. The Bigger Picture for Oncology in India The customs duty exemptions reduce import costs but do not guarantee proportional retail price reductions without corresponding NPPA pricing action. Ayushman Bharat still does not cover comprehensive genomic profiling or most immunotherapy regimens for the majority of patients. The Rs 10,000 crore biosimilars push is the more significant long-term lever since domestic biosimilar production of oncology drugs can reduce prices by 40-70% compared to originator imports. Watch for NPPA updates on maximum retail prices following the duty exemptions. Which 17 cancer drugs were exempted from customs duty in Budget 2026? The government confirmed Ribociclib and Brigatinib by name in budget documents. The full list of 17 drugs includes targeted therapies and immunotherapy agents primarily used in breast cancer, lung cancer, and rare oncological conditions. The complete official list is available in the Finance Ministry's customs notification accompanying Budget 2026-27. Oncologists should check this list against their current treatment protocols. Will patients actually pay less after the customs duty cut? Not automatically. Customs duty is one component of final retail price. Distributor margins, hospital markups, and GST also apply. The NPPA needs to revise the Maximum Retail Price (MRP) of these drugs to pass savings to patients. Historically there is a lag of several months between duty reduction and MRP revision. Tell patients that lower prices are likely coming but not to expect immediate changes at the pharmacy counter. Does Ayushman Bharat cover immunotherapy for cancer? Limited coverage only. PM-JAY covers certain chemotherapy regimens and some surgical oncology procedures under its Health Benefit Packages (HBPs). Most immunotherapy drugs, targeted therapies, and CDK inhibitors are not in the HBP list as of 2026. The middle-income patient bracket, above PM-JAY eligibility but below the ability to afford full out-of-pocket immunotherapy costs, remains the most underserved segment in Indian oncology. What is Ribociclib and who needs it? Ribociclib is a CDK4/6 inhibitor approved for HR-positive, HER2-negative advanced or metastatic breast cancer, used in combination with an aromatase inhibitor or fulvestrant. The MONALEESA trial series showed significant progression-free survival improvement. It is among the most prescribed targeted therapies in Indian oncology but was previously unaffordable for most patients without insurance. The customs duty removal directly improves access. What is the Rs 10,000 crore biosimilars fund and when will it affect oncology drug prices? Budget 2026-27 allocated Rs 10,000 crore to accelerate domestic biologics and biosimilars production through BIRAC and the National Biopharma Mission. It includes 3 new NIPERs and upgrades to 7 existing ones and strengthening of clinical trial sites. Price impact from domestic biosimilar scale-up typically takes 2-4 years to show at the retail level. Indian biosimilars for trastuzumab and bevacizumab already exist. The fund is expected to expand the pipeline to CDK inhibitors and checkpoint inhibitors. What should oncologists document when prescribing high-cost cancer drugs? Document the clinical indication, biomarker or genomic test result that supports the prescription (e.g., ALK FISH result for Brigatinib, HR/HER2 status for Ribociclib), the alternative options discussed with the patient, the patient's informed consent to cost and expected benefit, and the response monitoring plan. Insurer pre-authorization for high-cost drugs increasingly requires this documentation package, and it also protects you medico-legally if a patient later questions the treatment decision.